Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    iCo-007
Show Display Options
Rank Status Study
1 Completed Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema
Condition: Diffuse Diabetic Macular Edema
Intervention: Drug: iCo-007 Intravitreal Injection
2 Active, not recruiting A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)
Condition: Diabetic Macular Edema
Interventions: Drug: iCo-007 350 mcg;   Drug: iCo-007 700 mcg;   Drug: iCo-007 350 mcg Plus Laser;   Drug: Ranibizumab Plus iCo-007 350 mcg
3 Recruiting Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
Conditions: Pancreatic Neoplasms;   Digestive System Neoplasms;   Neoplasms by Site;   Neoplasms;   Endocrine Gland Neoplasms;   Pancreatic Diseases;   Digestive System Diseases;   Endocrine System Diseases;   Gemcitabine;   Antimetabolites, Antineoplastic
Interventions: Drug: nab-Paclitaxel 125 mg/m2;   Drug: gemcitabine 1000 mg/m2

Indicates status has not been verified in more than two years